Lupin gains on signing license and supply agreement with Zentiva
Lupin is currently trading at Rs. 1935.90, up by 14.20 points or 0.74% from its previous closing of Rs. 1921.70 on the BSE.
The scrip opened at Rs. 1924.20 and has touched a high and low of Rs. 1965.90 and Rs. 1924.20 respectively. So far 9391 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1767.15 on 09-Jul-2024.
Last one week high and low of the scrip stood at Rs. 1995.95 and Rs. 1915.00 respectively. The current market cap of the company is Rs. 88536.70 crore.
The promoters holding in the company stood at 46.92% while Institutions and Non-Institutions held 46.88% and 6.20% respectively.
Lupin has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of the company’s biosimilar Certolizumab Pegol. The company will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise.
The company will undertake commercialization in the remaining regions, including USA and Canada.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
